Carcinosarcoma

subtype

Identifier: CI-CAN-00000637
Entity page: /cancer/carcinosarcoma ↗
Edges: 229

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Carcinosarcoma investigated for …INVESTIGATED_FOR5 of 5
← investigated for	Pembrolizumabmonoclonal_antibody	unknown	2	Carcinosarcoma	1	Curated	chembl	graph →
← investigated for	Olaparibsmall_molecule	unknown	2

Carcinosarcoma altered in cohorts of …ALTERED_INderived15 of 101show all (up to 200)
← altered in cohorts of	TP53 52 / 57 cases (91 %) · ssm · TCGA-UCS · largest of 4 cohorts	—	—	Uterine Carcinosarcoma	4	Observed	gdc	graph →
← altered in cohorts of	MELTF 46 / 57 cases (81 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	PIK3CA 46 / 57 cases (81 %) · ssm · TCGA-UCS · largest of 4 cohorts	—	—	Uterine Carcinosarcoma	4	Observed	gdc	graph →
← altered in cohorts of	ADRM1 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	APOD 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A4 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A5 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	EEF1AKMT4-ECE2 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	FBXO45 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	FGF12 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	GATA5 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	LAMA5 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	MB21D2 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	MUC4 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	OPA1 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →

Carcinosarcoma altered in cohorts of …ALTERED_INderived15 of 101show all (up to 200)

← altered in cohorts of

TP53

52 / 57 cases (91 %) · ssm · TCGA-UCS · largest of 4 cohorts

—

Uterine Carcinosarcoma

Observed

Carcinosarcoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 46show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 14 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 10 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall_molecule 10 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall_molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Aldesleukinother 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall_molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Carcinosarcoma	2	Observed	clinicaltrials	graph →

Carcinosarcoma studied in …STUDIED_INderived10 of 77show all (up to 200)
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 77 trials mapped (24 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03651206Phase 2/Phase 3 · recruiting Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Ovarian Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06568172Phase 3 · suspended Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer · condition mapped CURATED_BROADER · 77 trials mapped (24 active)	—	—	Skin Squamous Cell Carcinoma with Sarcomatoid Differentiation	1	Observed	clinicaltrials	graph →
→ studied in	NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · condition mapped PROBABILISTIC · 77 trials mapped (24 active)	—	—	Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07741968NA · recruiting A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Ovarian Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05646316Phase 3 · recruiting Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Carcinosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 77 trials mapped (24 active)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 77 trials mapped (24 active)	—	—	Uterine Corpus Carcinosarcoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains